Figure 2
From: Evaluation of nimotuzumab Fab2 as an optical imaging agent in EGFR positive cancers
Analysis of Nimotuzumab pepsin digestion. (a) The percentage of IgG or fragments at different pepsin digestion time points are shown on the left y-axis and the sizes (kDa) are shown on the right y-axis. The column highlighted in grey shows the optimal time for pepsin digestion, which yields the most Fab2. The pepsin digestion time in hours (h) is shown on the x-axis. (b) Electronic electrophoresis analysis of Fab2 after pepsin digest and protein A clean up for IgG and Fc fragments. The peaks are labeled numerically, the first peak shows the 5 kDa lower marker, protein sizes are shown in kDa and the percent (%) of the total protein is shown. (c) Size exclusion analysis and purification of Fab2 after pepsin digest of each fraction. The different colors represent the percentage of each fragments size from each fraction. (d) Electronic electrophoresis analysis of the final Fab2 preparation. After pepsin digest, protein A clean up of IgG and Fc fragments, and size exclusion purification (collection of fractions 50–52).
